title: [Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
abstract: Bisphosphonates (BPs) are now widely used for the prevention of osteoporotic fracture. The elevation of bone turnover markers (BTM) is an independent risk factor for the bone fracture, and their significant decrease with BPs treatment is considered to reflect BPs' efficacy to "adjust" bone turnover. A large-scale study so far showed that BPs continuously suppress both BTM levels and the incidence of fracture as long as 7 to 10 years, though possible deterioration of bone strength with long-term severe suppression of BTM has been pointed out.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Fujita Health University.
authors.forename: Shogo
authors.initials: S
authors.lastname: Asano
authors.forename: Atsushi
authors.initials: A
authors.lastname: Suzuki
authors.forename: Mitsuyasu
authors.initials: M
authors.lastname: Itoh
mesh_terms: D019386:Alendronate / Q000008:administration & dosage; D015415:Biomarkers; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D016723:Bone Remodeling; D001842:Bone and Bones / Q000378:metabolism*; D004164:Diphosphonates / Q000008:administration & dosage*; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000175:diagnosis* / Q000188:drug therapy*; D000068296:Risedronic Acid; D013997:Time Factors
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate